Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
暂无分享,去创建一个
Saravudh Suvannadabba | J. Lang | K. Pengsaa | M. Saville | T. Wartel | N. Tornieporth | A. Bouckenooghe | A. Sabchareon | D. Wallace | C. Sirivichayakul | K. Limkittikul | P. Chanthavanich | S. Suvannadabba | Vithaya Jiwariyavej | Wut Dulyachai | A. Moureau | S. Viviani | Kriengsak Limkittikul | Alain Bouckenooghe | T Anh Wartel | Melanie Saville | Jean Lang | Chukiat Sirivichayakul | Pornthep Chanthavanich | Vithaya Jiwariyavej | Krisana Pengsaa | Wut Dulyachai | Arunee Sabchareon | Annick Moureau | Derek Wallace | Simonetta Viviani | Nadia G Tornieporth | T. Wartel
[1] S. Yoksan,et al. The Use of Dengue Nonstructural Protein 1 Antigen for the Early Diagnosis During the Febrile Stage in Patients With Dengue Infection , 2008, The Pediatric infectious disease journal.
[2] D. Francis,et al. Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials , 2003, AIDS.
[3] A. Barrett,et al. Yellow fever vaccine , 2005, Expert review of vaccines.
[4] V. Barban,et al. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. , 2012, Virology.
[5] Saravudh Suvannadabba,et al. Dengue Infection in Children in Ratchaburi, Thailand: A Cohort Study. II. Clinical Manifestations , 2012, PLoS neglected tropical diseases.
[6] G. Crane. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control , 1999 .
[7] Inacio Mandomando,et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.
[8] F. Guirakhoo,et al. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates , 2000, Journal of Virology.
[9] H. Margolis,et al. Dengue Infection in Children in Ratchaburi, Thailand: A Cohort Study. I. Epidemiology of Symptomatic Acute Dengue Infection in Children, 2006–2009 , 2012, PLoS neglected tropical diseases.
[10] Aidan McDermott,et al. The Impact of the Demographic Transition on Dengue in Thailand: Insights from a Statistical Analysis and Mathematical Modeling , 2009, PLoS medicine.
[11] A. Nisalak,et al. A plaque reduction test for dengue virus neutralizing antibodies. , 1967, Journal of immunology.
[12] J. Hombach. Guidelines for clinical trials of dengue vaccine in endemic areas. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[13] Charles H. Hoke,et al. SEROTYPE-SPECIFIC DENGUE VIRUS CIRCULATION AND DENGUE DISEASE IN BANGKOK, THAILAND FROM 1973 TO 1999 , 2003 .
[14] I. Bosch,et al. Population dynamics of DENV-1 genotype V in Brazil is characterized by co-circulation and strain/lineage replacement , 2012, Archives of Virology.
[15] L. Peruski,et al. Development and Evaluation of Serotype- and Group-Specific Fluorogenic Reverse Transcriptase PCR (TaqMan) Assays for Dengue Virus , 2001, Journal of Clinical Microbiology.
[16] H. Margolis,et al. Best Practices in Dengue Surveillance: A Report from the Asia-Pacific and Americas Dengue Prevention Boards , 2010, PLoS neglected tropical diseases.
[17] Duane J. Gubler,et al. The Economic Burden of Dengue , 2012, The American journal of tropical medicine and hygiene.
[18] C. Lanata,et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. , 2012, Vaccine.
[19] P. Gething,et al. Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus , 2012, PLoS neglected tropical diseases.
[20] N. Breslow,et al. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.
[21] Richard G Jarman,et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. , 2007, The American journal of tropical medicine and hygiene.
[22] M. Diamond,et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions , 2012, Proceedings of the National Academy of Sciences.
[23] D. Clements,et al. Dengue vaccines: progress and challenges. , 2011, Current opinion in immunology.
[24] J. Lang,et al. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity , 2011, The Pediatric infectious disease journal.
[25] L. Shek,et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years , 2012, Human Vaccines & Immunotherapeutics.
[26] A. Barrett,et al. Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. , 2008, Viral immunology.
[27] M. Guzmán,et al. The epidemiology of dengue in the americas over the last three decades: a worrisome reality. , 2010, The American journal of tropical medicine and hygiene.
[28] B. Murphy,et al. Immune response to dengue virus and prospects for a vaccine. , 2011, Annual review of immunology.
[29] N. Lennon,et al. Emergence of the Asian 1 Genotype of Dengue Virus Serotype 2 in Viet Nam: In Vivo Fitness Advantage and Lineage Replacement in South-East Asia , 2010, PLoS neglected tropical diseases.
[30] B. Guy,et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. , 2011, Vaccine.
[31] B. Guy,et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. , 2009, The American journal of tropical medicine and hygiene.
[32] S. Halstead,et al. Japanese encephalitis: new options for active immunization. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Cameron P. Simmons,et al. Current concepts: Dengue , 2012 .
[34] J. Lang,et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. , 2011, Vaccine.
[35] Stephen J. Thomas,et al. Critical issues in dengue vaccine development , 2011, Current opinion in infectious diseases.
[36] A. D. de Silva,et al. The Human Antibody Response to Dengue Virus Infection , 2011, Viruses.
[37] Stephen J. Thomas,et al. Vaccines for the prevention of dengue: Development update , 2011, Human vaccines.